Jane Street
LXRX icon

Jane Street’s Lexicon Pharmaceuticals LXRX Stock Holding History

Jane Street’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$871K Buy
558,500
+454,400
+437% +$661K ﹤0.01% 6817
2025
Q4 		$120K Buy
+104,100
New +$143K ﹤0.01% 10084
2025
Q3 		– Sell
-62,600
Closed -$59.2K – 11363
2025
Q2 		$59.2K Buy
+62,600
New +$40.6K ﹤0.01% 9130
2024
Q3 		– Sell
-495,800
Closed -$833K – 10076
2024
Q2 		$833K Sell
495,800
-45,500
-8% -$81.6K ﹤0.01% 6122
2024
Q1 		$1.3M Buy
541,300
+530,600
+4,959% +$1.14M ﹤0.01% 4922
2023
Q4 		$16.4K Sell
10,700
-7,600
-42% -$9.04K ﹤0.01% 8930
2023
Q3 		$19.9K Sell
18,300
-52,700
-74% -$92.5K ﹤0.01% 8307
2023
Q2 		$163K Buy
+71,000
New +$188K ﹤0.01% 7768
2023
Q1 		– Sell
-21,600
Closed -$41.3K – 9542
2022
Q4 		$41.3K Sell
21,600
-5,900
-21% -$12.6K ﹤0.01% 8426
2022
Q3 		$66K Buy
+27,500
New +$76.1K ﹤0.01% 8824
2022
Q1 		– Sell
-10,000
Closed -$39K – 10721
2021
Q4 		$39K Sell
10,000
-5,100
-34% -$24.8K ﹤0.01% 9614
2021
Q3 		$73K Buy
+15,100
New +$62K ﹤0.01% 9411

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street's LXRX Position: Q1 2026 in Review

Jane Street increased its Lexicon Pharmaceuticals (LXRX) stake by 55% in Q1 2026, buying an estimated $1.37M and bringing the position to 2,665,938 shares worth $4.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3778.

Jane Street first reported a position in LXRX in Q3 2013 and has held it in 25 quarters since. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Jane Street held 2,665,938 shares of Lexicon Pharmaceuticals worth $4.16M as of Q1 2026.
  • Jane Street bought 941,634 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $1.37M.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3778 holding.
  • Jane Street first reported a position in Lexicon Pharmaceuticals in Q3 2013 and has held it in 25 quarters since.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.